6.08
-0.01(-0.16%)
Currency In USD
| Previous Close | 6.09 |
| Open | 5.98 |
| Day High | 6.26 |
| Day Low | 5.82 |
| 52-Week High | 12.65 |
| 52-Week Low | 5.82 |
| Volume | 8.08M |
| Average Volume | 3.49M |
| Market Cap | 1.87B |
| PE | -67.56 |
| EPS | -0.09 |
| Moving Average 50 Days | 7.92 |
| Moving Average 200 Days | 9.78 |
| Change | -0.01 |
If you invested $1000 in Amicus Therapeutics, Inc. (FOLD) 10 years ago, it would be worth $565.06 as of May 09, 2025 at a share price of $6.08. Whereas If you bought $1000 worth of Amicus Therapeutics, Inc. (FOLD) shares 5 years ago, it would be worth $503.73 as of May 09, 2025 at a share price of $6.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference
GlobeNewswire Inc.
May 07, 2025 11:00 AM GMT
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2025 Health Care Conference in Las Vegas, NV on Wednesday, May 14, 2025,
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
GlobeNewswire Inc.
Apr 30, 2025 11:12 PM GMT
Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and fatal kidney disease with no FDA-approved therapies Dimerix succes
Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025
GlobeNewswire Inc.
Apr 21, 2025 11:00 AM GMT
PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to discuss financial results for th